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Abstract 
Older people are disproportionately affected by the COVID-19 pandemic, which has had a profound 
impact on research as well as clinical service delivery. This commentary identifies key challenges and 
opportunities in continuing to conduct research with and for older people, both during and after the 
current pandemic. It shares opinions from responders to an international survey, a range of 
academic authors and opinions from specialist societies. Priorities in COVID-19 research include its 
specific presentation in older people, consequences for physical, cognitive and psychological health, 
treatments and vaccines, rehabilitation, supporting care homes more effectively, the impact of social 
distancing, lockdown policies and system reconfiguration to provide best health and social care for 
older people.  COVID-19 research needs to be inclusive, particularly involving older people living with 
frailty, cognitive impairment or multimorbidity, and those living in care homes. Non-COVID-19 
related research for older people remains of critical importance and must not be neglected in the 
rush to study the pandemic. Profound changes are required in the way that we design and deliver 
research for older people in a world where movement and face-to-face contact are restricted, but 
we also highlight new opportunities such as the ability to collaborate more widely and to design and 
deliver research efficiently at scale and speed. 
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Introduction 
The Coronavirus Disease 2019 (COVID-19) pandemic has challenged healthcare systems across the 
world in a way not seen in modern times. Older people are bearing the brunt of the pandemic as a 
group at the highest risk of hospitalization and death from COVID-19 illness [1,2], but they are also 
significantly affected by the loss of social contact, constraints on movement, disrupted supply chains 
and loss of non-COVID-19 healthcare that are all consequences of the response to the pandemic. 
Research is a core component of the global response to COVID-19 [3], but the pandemic has had an 
enormous impact on our ability to design and deliver all research for older people, not just for 
COVID-19. The aim of this article is to identify what the priority areas are for COVID-19 research for 
older people, but also to consider how the design and delivery of research for older people will need 
to change during and after the pandemic. We pool the expertise of an international team of authors, 
guidance from specialist societies, and results from an international panel of survey respondents 
engaged in research and clinical care for older people.  
 
Priorities in research for older people in a world with COVID-19 
Much of the narrative around research for COVID-19 in the scientific and popular press has focussed 
on epidemiology, treatment (predominantly drug treatment) and vaccines. As part of the 
preparation for this commentary, we undertook a survey of researchers and clinicians specialising in 
the care of older people from the UK, Europe and across the world.  The survey aimed to gain their 
views on priorities for research with older people and lasting impacts on design and delivery of 
research. Full details of the survey methods and results are given in the Supplementary material. Key 
priorities identified by the 267 respondents are given in Table 1. 
  
 
 
Table 1. Priorities identified for COVID-19 research for older people  
(Priorities are listed in order from most to least frequently mentioned in survey responses) 
Priorities 
 
 
 
Examples of themes mentioned  
Management of COVID and its 
complications 
 
 
drug treatment trials, managing complications including 
delirium, end of life care, rehabilitation, outcomes following 
intensive care unit admission 
Epidemiology 
 
 
 
presentation in older subgroups, prognosis, impact on 
frailty and function, health inequalities, accurate mortality 
data 
Wider societal impact of COVID 
 
 
 
impact of lockdown measures on older people, maintaining 
mobility, elder abuse, impact on carers 
Consequences of the pandemic for 
other healthcare delivery 
telemedicine and remote delivery of treatment including 
rehabilitation, impact of postponed investigation and care, 
access to primary and secondary care, delivering care safely 
with PPE, experience of hospital care, care delivery models 
Care home research 
 
 
 
epidemiology and outcomes in care home residents, impact 
on care home staff, transmission prevention, end of life 
care, building capacity for research within care homes 
Public health interventions 
 
 
 
vaccines, impact of social distancing on infection, 
interventions to promote healthy behaviours, access to 
testing 
Communication in pandemic 
situations 
 
 
with relatives, use of technology, advance care planning, 
bereavement, death certification 
Pathophysiology of COVID infection in 
older people 
 
 
immune response, transmission, why older people are at 
higher risk 
Research methodology inclusion of older people in COVID research, older people’s 
voice in priority setting, patient reported outcomes and 
remote data collection, how to continue to deliver research 
safely, how research is publicised and disseminated 
 
  
 
 
A recent position statement by the British Geriatrics Society highlights some of these areas as key for 
future research into COVID-19 and older people [4]. A critical missing voice for COVID-19 research 
for older people is that of older people themselves. We need to know what older people view as 
priorities, and there is an urgent need to solicit their opinions on this. Such an exercise must be 
sufficiently inclusive and deliberative to provide robust findings that can underpin research choices 
over months to years. This could be delivered using existing structures such as the James Lind 
Alliance, who recently completed a similar exercise setting priorities for research for people living 
with multiple long-term conditions [5]. In concert, qualitative research on the lived experience of 
older people with COVID-19, their carers and families, and its wider consequences is needed to 
complement understanding from epidemiological studies and to underpin the design of 
interventions. 
 
Making COVID-19 research inclusive 
Studies have not always been designed to enable inclusion of people at high risk of the adverse 
consequences of COVID-19; a third of COVID-19 related trials identified by a recent review had an 
arbitrary and unjustified upper age cut-off [6], and exclusion criteria for trials too often prevent 
people with multimorbidity from taking part [7]. Given that the impact of COVID-19 is greatest for 
older people, it is vital that they are included in such studies. Therefore, studies must be designed to 
enable safe participation from a broad range of populations, including those living in care homes, 
and avoid exclusion because of age, multimorbidity or frailty. Including these groups does not come 
naturally to all clinical specialities or to industry partners, and academics with expertise in research 
for older people have a key role in collaborating with others to facilitate inclusion of these 
underserved groups. Such collaboration across multiple specialities is particularly important given 
the multisystem nature of COVID-19 [8].   
 
 
 
Although most trials to date have focussed on hospitalised patients, large platform trials such as the 
PRINCIPLE trial (Platform randomised trial of interventions against COVID-19 in older people) show 
that recruitment from community-dwelling populations is possible [9].  However, a focus on place of 
care or place of residence alone is insufficient; other barriers to participation such as cognitive 
impairment and lack of capacity need to be addressed and overcome. Some trials have done so 
successfully by accepting enrolment in best interests in emergency situations, such as is the case for 
the RECOVERY trial testing treatments in hospitalised patients with COVID-19 [10]. Whilst this is not 
appropriate for all types of study, the danger to life and function posed by COVID-19 infection to 
these most vulnerable groups justifies such an approach, with appropriate governance and clinical 
research expertise. 
 
Technology can improve some aspects of inclusivity, as shown by the ability of videotelephony 
products to enable housebound individuals, hospital patients and care home residents to stay in 
touch with their families during the pandemic.  However, it also carries risks of disenfranchising 
some older people, particularly without adequate training. Care is thus needed to ensure that in 
using technology to improve access to research for some participants, we do not exclude others – 
particularly older people without the hardware, connectivity, skills, cognition, vision or support to 
use mobile phones or computers [11].  Maintaining choice in how participants interact with research 
teams remains important and technology needs to be used as part of a flexible package of 
communication methods, alongside traditional telephone and face-to-face approaches. Research is 
needed to understand how best to make these solutions work for the widest range of older people, 
including those with sensory or cognitive impairment, and existing knowledge needs to be 
disseminated rapidly to research teams for incorporation into new study designs.   
 
 
 
Changes in how we deliver research for older people 
Much clinical research has traditionally been conducted via face-to-face contact.  However, full or 
partial lockdowns in many countries in response to the COVID-19 pandemic have exposed the 
weaknesses of this approach and made it difficult if not impossible to conduct face-to-face research. 
When face-to-face research does take place, personal protective equipment (PPE) is necessary for 
participants and research staff, which can impact on communication, as well as on the development 
of rapport. In the UK, face-to-face research has been drastically scaled back, both to reduce risk to 
participants and because research staff have been diverted to COVID-19 research or clinical service 
delivery. Face-to-face follow-up for some clinical trials continues but new recruitment into many 
studies has stopped, as has face-to-face follow up of observational studies. These are challenges for 
traditional models of research participation, but also require changes to how we engage older 
people in the broader research process. Patient and public involvement and engagement in design, 
delivery and dissemination is now more important than ever and new processes to enable this in the 
absence of travel and face-to-face meetings are needed.  
 
Changes to study recruitment 
COVID-19 has interrupted many clinical services, particularly non-emergency services. Such services 
(both in primary and secondary care) often provided the substrate for identifying and recruiting 
older people into clinical trials. The way that clinical services are delivered is likely to change 
permanently as a result of the COVID-19 pandemic, with more remote consulting, and a shift in 
delivery of services via community rather than hospital teams. Traditional methods of finding and 
recruiting participants, for instance via advertisements and approaches in clinics, cannot take place if 
older people do not attend healthcare facilities during a pandemic, and will not be fit for purpose if 
the traditional clinical service model changes to one with a high degree of community contact and 
remote working. New methods to recruit and consent participants will be needed. These changes 
 
 
provide an opportunity to conduct research differently, reaching participants in different ways and 
potentially reaching groups who we currently struggle to engage in research. Alternative 
communication channels, including radio and television advertisements, social media, targeted 
mailshots and web-based publicity can all contribute to study recruitment, and systems of remote 
consent (E-consent systems and witnessed telephone or video consent) [12]) will also have a role to 
play. However it will be just as important to ensure that research forms part of the conversation 
with a much wider range of healthcare professionals outside the hospital or research institute. Care 
home staff, community nurses, exercise practitioners and primary care teams all have a role to play 
in promoting research to older people. 
 
Disease registries have been used with variable success to identify and contact research participants 
and may provide an alternative to clinic or primary care recruitment for some people, particularly if 
access can be facilitated by carers or family members [13]. However, such registries will only be of 
use if they include patients with multimorbidity rather than a single, narrowly defined disease. 
Identification of participants via electronic health records is increasingly used [14], and new 
technologies such as natural language processing hold out the promise of identifying older people 
with complex, poorly-defined sets of conditions (e.g. frailty, functional impairment) without face to 
face assessment.  
 
Changes to study assessments and outcomes 
Bringing older people to clinic or hospital-based research appointments is likely to remain difficult in 
the short term, due to restrictions on movement, constraints on public transport use, fear of 
healthcare facilities, and strains on healthcare system capacity.  Such problems will be magnified in 
future pandemic waves and highlight the need for a much more robust and flexible portfolio of 
follow-up mechanisms within clinical studies. Embedding research assessments within routine clinic 
 
 
visits will help to minimise travel and contact with others. Visiting participants in their own homes 
(with appropriate personal protective equipment) may be necessary where study procedures must 
be conducted face-to-face and travel outside the home is impossible, and physical separation of 
hospital and research facilities may reassure some participants who are otherwise reluctant to 
attend. Even these solutions may not work for all groups; stigma associated with visits from staff 
wearing PPE, and reluctance of care homes to allow researchers to visit are potential barriers. 
 
The COVID-19 pandemic has forced researchers to move to remote follow-up by telephone or video, 
or to defer or abandon follow-up altogether. Remote follow-up is not possible for all outcomes but 
such approaches may provide a compromise to enable some follow-up where otherwise none would 
be possible.  Increased use of postal, telephone and video follow up, posting or delivering study 
medications to participants, and the use of remote sensing technologies (e.g. accelerometers and 
other phone/Bluetooth enabled devices) is likely to be necessary. However, such technologies 
require validation and evaluation in a range of older populations and conditions as a matter of 
urgency, as exemplified by the work of the EU-funded MOBILISE-D consortium (www.mobilise-d.eu). 
With the increasing use of electronic healthcare records, it is now possible to use routinely-collected 
clinical data as an additional source of outcomes data, which minimises loss to follow up and 
reduces the number of healthcare contacts that an individual needs to undergo. Successful use of 
such data sources requires that outcomes relevant to research are recorded, and in a reliable and 
consistent way – the obverse of which is that clinical studies need to select outcomes that are 
already accurately recorded in routine clinical practice. Where routinely-collected data are not fit for 
purpose (an example being that individuals living in care homes cannot be easily identified from 
records, or when key outcomes are not measured or recorded in routine data), the COVID-19 
pandemic needs to catalyse efforts to improve the range and quality of data held in the electronic 
patient record.  
 
 
 
Research for COVID-19 has also reinforced the value in having agreed, simple sets of core outcome 
measures focussed on a small number of study questions [15] (such as the WHO ordinal scale for 
COVID-19 outcomes) [16]; too many studies for older people are dogged by overly complex sets of 
outcome measures which differ between studies leading to burden on participants and difficulties in 
pooling data. In parallel with these changes, other study processes including study monitoring, data 
entry and data verification need to adapt to the constraints of the pandemic; electronic data capture 
avoids contamination of paper case records, remote monitoring avoids the need for site visits by 
monitors, and the use of electronic health records enables remote data verification without travel or 
on-site access. 
 
Future-proofing studies 
We do not know how many pandemic waves there will be or indeed whether the world will have to 
live with COVID-19 as an endemic infection with long-term controls on movement of people and 
healthcare contact. Consequently, research must be robust against future shocks to the healthcare 
system and to research delivery. This means, wherever possible, significant redesign of existing 
studies, embedding key principles of flexibility and resilience into future study designs. Changing our 
delivery mechanisms will ensure that if another pandemic wave hits, research – directly related to 
COVID-19 but also on all issues relating to health and social care of older people - can still be 
delivered and will not grind to a halt. In order to make this a reality, much more emphasis will need 
to be placed on collaborative working and multicentre studies – single centre studies are slow to 
recruit and vulnerable to local pandemic disruption. Strong links and continuous dialogue with 
emerging research findings, funders, patients and the public will be necessary to ensure that the 
research agenda responds quickly to the needs of patients and policymakers as the pandemic 
progresses. 
 
 
 
Opportunities and challenges in non-COVID-19 research 
One of the biggest challenges to non-COVID-19 research for older people is currently COVID-19. As 
discussed, the pandemic has made research hard to conduct in practice, but it has also diverted the 
time and resources of investigators, funders, regulators and delivery teams away from non-COVID-
19 research. No new non-commercial studies were supported for recruitment by the NIHR Clinical 
Research Network in the UK after March 16th 2020 other than urgent, prioritised COVID-19 studies 
[17]. Similar data from a survey of the British Association of Stroke Physicians highlighted that the 
majority of UK stroke research projects had been halted and all responding sites had seen a 
substantial decrease in stroke research activity. The economic shock delivered by the pandemic is 
likely to lead to significant cuts to public and charity budgets across the world, and it is unclear to 
what extent this will affect medical research [18]. Even if medical research budgets are preserved, 
COVID-19-related research is now likely to compete with non-COVID-19 research.   
 
The key lesson to be learned from successful COVID-19 research is that doing fewer studies at larger 
scale pays dividends – duplication is reduced, participants can be recruited and data collected at 
speed, and results are more robust. The COVID-19 pandemic has shone a harsh light on the wasted 
effort and opportunity in conducting small or poorly designed studies, which have had a 
disproportionate and often adverse impact on public discourse and policymaking [19]. Successful 
international collaborations [20] have enabled rapid learning from cross-country comparisons. These 
lessons remain relevant to all research for older people. 
 
Wise funders and researchers will need to find ways to combine the study of COVID-19 with 
important non-COVID-19 research priorities, ensuring that we continue to improve diagnosis and 
treatment of frailty, sarcopenia, bone health, dementia, delirium, stroke, movement disorders, 
incontinence and the other myriad conditions that affect older people. The COVID-19 pandemic has 
brought the concept of frailty to a much wider audience, and the pandemic has also highlighted the 
 
 
needs of the care home sector and the importance of mental health in older people. These are 
opportunities to be capitalised upon, and it is essential that researchers continue to focus on a broad 
range of conditions of importance; skewing the research agenda toward COVID-19 at the expense of 
these other conditions does a disservice to our patients. The pivotal role of discovery science and 
experimental medicine in the COVID-19 response should also stimulate clinical researchers to work 
more closely with our preclinical colleagues – the answers to diseases of ageing lie in translating 
insights from the laboratory through into clinical research at much greater speed and volume than 
has been the case until now. 
 
The interruption to normal clinical and research activity is a challenge to our research workforce. 
Established practitioners may need to drastically change their approach to research focus, design 
and delivery, taking many out of their comfort zone and adding stress to a research culture that is 
already heavily performance-driven. Conversely, the pandemic response gives the academic 
community an opportunity to refocus on what is really important in research, rather than the 
current narrow set of performance measures. Supporting emerging researchers in a time of 
uncertainty will also be essential [21]; clinical academic trainees including nursing and allied health 
professions colleagues have paused research to return to clinical duties and many non-COVID clinical 
and laboratory projects have been paused. The pandemic risks disrupting career progression which 
depends on project completion, obtaining grants or fellowships; a flexible approach to assessing 
career milestones, research degree progress and fellowship applications should be applied by 
funders.  
 
History teaches us that all periods of disruption bring benefits as well as setbacks and it is important 
to reflect on the gains that the research community will have made during this pandemic. We are 
finding new ways to work, building new collaborations, and benefitting from cross-fertilisation of 
 
 
ideas and techniques as we learn at speed from colleagues; it is heartening to see plans for a 
European Geriatric Medicine Society virtual conference dedicated to COVID-19 for just these 
purposes [22]. This learning, if properly used, will enhance research for older people, and we have a 
duty to ensure that these benefits deliver faster, better research for older people both during the 
pandemic and in the years to come.  
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